Novo Nordisk’s SELECT Trial Shows Semaglutide 2.4 mg Cuts Cardiovascular Risk in Overweight and Obese Adults

(IN BRIEF) Novo Nordisk, a global healthcare company, has reported the headline findings from the SELECT cardiovascular outcomes trial. This double-blinded study assessed the impact of subcutaneous once-weekly semaglutide 2.4 mg in comparison to placebo as an adjunct to standard … Read the full press release →